Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

China Accepts NCX 470 NDA for Review in Glaucoma Treatment

12 September 2026 · By · Wire by Fusion42

Published

12 September 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

China

◆ Source

Read at clinicaltrialvanguard.com →

◆ Verified

Fusion42 · 12 September 2026 · Fusion42 review

China's drug regulator has accepted Nicox's NDA for NCX 470, a nitric oxide-donating eye drop for glaucoma, initiating a formal review cycle based on existing global clinical data without requiring local trials.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

Chinese regulatory acceptance opens a new market for glaucoma treatments, but you must prepare for a lengthy review and secure financial runway to bridge the gap between approval and revenue.

◆ Coverage

1 source · 12 Sep 2026

◆ Related on Wire

◆ Topics

Medtechglaucoma-treatmentncx-470china-ndadrug-approvalophthalmology